| P/E (FY) | 22.4 | Sales (TTM) | SEK 6.52B |
| Earnings (TTM) | SEK 366.0M | ROE | 14.44% |
| Net Margin | 5.61% | ROIC | 13.26% |
| Debt / Equity | 1.02 | TD / EBITDA | 1.63 |
| EPS Growth 3Y | 60.48% | Sales Growth 3Y | 11.32% |
Synsam AB operates in the optical retail and eye health sector in the Nordic region. It sells lenses, frames, sunglasses, sports spectacles, contact lenses, eye care accessories, and hearing aids, and provides services such as eye examinations, hearing tests, personal style advice, and lens subscriptions. The company reaches customers through directly owned and franchised stores and e-commerce in Sweden, Denmark, Norway, Iceland, the Faroe Islands, and Finland, under brands including Synsam, Profil Optik, Oscar Eide, and EyeQ. Synsam was founded in 1968 and is headquartered in Stockholm, Sweden.
| Market Cap | $843.1M | Trading Days | 1138 |
| 52W High | 72.10 |
| 52W Low | 50.90 |
| % Off High | −22.88% |
| YTD | −15.16% | 1Y | 5.07% |
| 3Y | 42.75% | Since incept. (ann.) | 4.32% |
| Ann. Volatility (1Y) | 28.70% | Ann. Volatility (3Y) | 33.06% |
| Sharpe (1Y) | 0.32 | Sharpe (3Y) | 0.57 |
| Max Drawdown (1Y) | −24.23% | Max Drawdown (3Y) | −30.44% |
| Beta (3Y, vs SPY) | 0.60 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MCAP.ST | MedCap AB (publ) | $858.5M | 39.8 |
| KURA | Kura Oncology, Inc. | $826.5M | — |
| CMMB | Chemomab Therapeutics Ltd. | $822.8M | 79.4 |
| ESPR | Esperion Therapeutics, Inc. | $818.6M | — |
| TBPH | Theravance Biopharma, Inc. | $870.7M | 8.2 |
| OMER | OMEROS CORP | $816.4M | — |
| ABUS | Arbutus Biopharma Corp | $871.1M | — |
| TALK | Talkspace, Inc. | $872.7M | 130.3 |
| MEDCL.PA | MEDINCELL S.A. | $878.9M | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $888.5M | 9.9 |
| AVR | Anteris Technologies Global Corp. | $795.3M | — |
| SIBN |
| SI-BONE, Inc. |
| $795.2M |
| — |
